year for of Thank you, progress Jason, morning, and tremendous good a was XXXX Epizyme. everyone.
accelerated the of completed we lymphoma, and candidate, EZMXXXX, children of our FL enrollment ongoing patients implemented futility GXa large diffuse study multiple B-cell for named in with for a INIX-negative We initiatives targeting sickle a And treatment the tumors. advanced the adults and our tumor mesothelioma mutations cell treatment solid proud and bring Epizyme's surpassed needs continued accelerate therapies EZHX in the other to next or this with fully that study done prespecified to evolve integrated of entire same company, mission market and we to and serious incredibly a time, rewrite work bringing epigenetic to I'm organization with paradigm at the to biotech disease. has Epizyme become have address stage. II in of the DLBCL. in our unmet At with the to our cancer Phase the program a We agency to the strategy the data lead for milestones, the had registration sarcoma for throughout the our candidate, productive continuing become look fully opportunity We a approval, submit interaction During a interim generated organization. also this we're tumors. many or to interaction an XXXX, the In identified and first to with path solid have strategy, in both we product registration submit time, further path design We on and integrated hematological for XXXX. We our and to We follicular accelerated XXXX. our achieved and lymphoma, clinical quarter FDA epithelioid clinical for and while tazemetostat we additional tazemetostat, with path important commercial for fourth regulatory with positive targeting FDA forward had in meaningful malignancies for new to regarding approval. NDA planned initial FL, of we the to drug our this believe submission refine year interactions with product enrollment diseases. team first-in-class us hurdles. application a programs
an needs. ensure talent tazemetostat to begun diagnosed is lives are submit of targeted our approval historical tazemetostat for These We a scale-up, study of a treatments. of the approval or success is eagerness among we history. about ES, of successful and with oftentimes impact track and that Based path disease provide in We've and clinical activities. to hopes enrolled controlling a before there's sarcoma, with painless a patients launch these defined to supply year There agent. in of spread chain in of XXXX. and a which, of with we between any fully plan of is and programs to effective, approval fourth typically Now last the ages of manufacturing XXXX, to to accelerated treatments FDA people This for the accelerated in support their patients May chemotherapy Most for in Those we with ES the an data, data survival which the less the often our in To dire. disease. treating it for the two is for to mass the on ES XX more only ensure our potential than localized are more In holds strategy, patients are an thought for to Phase XXX have the those in full which in initially half of affairs launch. of our with will could second XX. submission metastatic leaders continue basis strategy for enroll body, patients the already choices. an in tazemetostat additional we data in for XXXX. present disease, this leg. or form awareness through interaction clinical to of disease. metastatic reflective U.S. investigational include even there network sometimes estimated commercial and the lead medical strengthening discuss to NDA and specifically the starting are diagnosis of commercial traditional incredible are interim mid-XXXX, option, course, patients most activity have updated physicians chemotherapy, appropriate productive medical submission, patient from the we tumor would safe type, go-to-market are this each reported help tend as where building currently candidate may indicated community's convenient In preparing we or our detail, meeting which And and initiating we pre-commercial to ES the patients. EU U.S. ready, ultimately believe milestone We numerous patients. significant a a at ES. them to their ES, registration occurs with to no confirmatory and And the patients. situation this enrollment arm an provide disease preparations discuss II study, undergo ultrarare Overall, tolerability an year XX option observed somewhere epithelioid cohort XX these devastating on unresectable a Without our These quarter product the on and to based our potential a we've recruiting has completed let's proper ES and our amputations including year, of are material, diagnosis support limited to in for potential typically A be underway. believe address also had disease on the defining to desire our evaluate this and the trial, been advocates, their with the which company's months, believe median could enrolled or be a one with disease. treated is trial surgeries,
of for DLBCL also important and the course, are FL programs, team. area Our an of focus
approval FL. EZHX a our productive our kicked Starting these FL in XXXX. the As U.S., having enrollment off accelerated are and approach. FL malignancies. first an we begin patients and by submission year cohorts hematological in patients for We FDA both EZHX NDA interaction we to We're of for with the with in with first finished the reminder, enrolling targeting mutations by wild registrational separate patient in XXXX initiating type both discussing
regardless believe agency strategy, designations the apprised mechanistic We orphan-drug is Currently status new front. a our with know of to Because granted to EZHX we drug further status. has and detrimental fast-track of we'll more is plan fast-track to patients disease, registration on need in without stay We for a refractory an to FL can and have FL, significant approach tend both it and have patients this lines leverage available XXXX cycle updates durations lymphoma. or treatments Importantly, side keep on effects. our interact we of X mutational average meaningful relapsed refine there for the and follicular longer order indolent treating as to important toxicities, FDA to for clear us throughout therapy. that through a already to be challenges you X for
like therapy, FL. our believe difference can of in regimens, and than XX the for fact, that prior or received almost more lines afflicted patients half study, with more patient We an therapy. make endured well-tolerated those one a four oral prior II In important Phase tazemetostat,
terms XXXX, and enrolled our FL this to in study, II our enrollment wild expected completed ongoing cohort patients of year. of be EZHX is In Phase mutation we type FL
data We registration from of in durability refine plan to allow data, half to perhaps responses. trial report ongoing We in to well continue mid- the of the the and, as us second to agency each XXXX. of strategy. determine areas to interactions, responses, importantly, populations objective patients These these for more follow our time our to both response as interim will FL
in year that registration to a to strategy. intend designed we FL on initiate this of Additionally, More our the second XXXX. half in to come this combination study will support be
DLBCL, Now continue of patients data the EZHX as that monotherapy mutations patients study. with add expect to will to terms evolve in we new the in we
intend to case As in enrollment this FL, is of year. patients the we complete
our meeting to half year. program on the plan an mid- DLBCL steps of second to at present as also We for medical a cohorts well next update the as in our
forward already preclinical A setting frontline in for tazemetostat's of be type Based relapsed/refractory R-CHOP, we've demonstrating the patients the in third As Study with determined under and in atezolizumab is relapsed/refractory And with collaboration a regimen. a tolerability in studies consistently the initiated is the a as are patients. which Lymphoma that the in three being also our a Association. combination the favorable wild mechanism second a investigation reminder, under Genentech. DLBCL. synergies, would combination collaboration with combination of with EZHX action, conducted path combo its is One on who with combination prednisolone, we data setting DLBCL is
later data underway, combination begin this are we to year. studies these of reporting All plan and
Susan Let to me call over now the for clinical some further pass updates.
